Investigación

Dianas farmacológicas en inflamación y enfermedades metabólicas

Buscador de publicaciones

Publicaciones

  • Aguilar-Recarte D, Palomer FX and Vazquez M.

    Uncovering the role of apolipoprotein C-III in insulin resistance

    Clinica e Investigacion en Arteriosclerosis . 33(2): 108-115. Nº de citas: 1

    [doi:10.1016/j.arteri.2020.09.003]

  • Sala E, Vived C, Luna J, Saavedra-Ávila NA, Sengupta U, Castaño AR, Villar-Pazos S, Haba L, Verdaguer J, Ropero AB, Stratmann T, Pizarro J, Vazquez M, Nadal A, Lahti JM and Mora C.

    CDK11 Promotes Cytokine-Induced Apoptosis in Pancreatic Beta Cells Independently of Glucose Concentration and Is Regulated by Inflammation in the NOD Mouse Model.

    FRONTIERS IN IMMUNOLOGY . 12: 634797-634797. Nº de citas: 1

    [doi:10.3389/fimmu.2021.634797]

  • Zarei M, Aguilar-Recarte D, Palomer FX and Vazquez M.

    Revealing the role of peroxisome proliferator-activated receptor beta/delta in nonalcoholic fatty liver disease

    METABOLISM-CLINICAL AND EXPERIMENTAL . 114: 154342-154342. Nº de citas: 21

    [doi:10.1016/j.metabol.2020.154342]

  • Codony S, Pujol E, Pizarro J, Feixas F, Valverde E, Loza MI, Brea JM, Saez E, Oyarzabal J, Pineda-Lucena A, Pérez-Dueñas B, Pérez C, Rodríguez-Franco MI, Leiva R, Osuna S, Morisseau C, Hammock BD, Vazquez M and Vázquez S.

    2-Oxaadamant-1-yl Ureas as Soluble Epoxide Hydrolase Inhibitors: In Vivo Evaluation in a Murine Model of Acute Pancreatitis

    JOURNAL OF MEDICINAL CHEMISTRY . 63(17): 9237-9257. Nº de citas: 14

    [doi:10.1021/acs.jmedchem.0c00310]

  • Barroso E, Rodríguez-Rodríguez R, Zarei M, Pizarro-Degado J, Planavila A, Palomer FX, Villarroya-Gombau F and Vazquez M.

    SIRT3 deficiency exacerbates fatty liver by attenuating the HIF1 alpha-LIPIN 1 pathway and increasing CD36 through Nrf2

    CELL COMMUNICATION AND SIGNALING . 18(1): 147-147. Nº de citas: 18

    [doi:10.1186/s12964-020-00640-8]

  • Zarei M, Pizarro J, Barroso E, Palomer FX and Vazquez M.

    Targeting FGF21 for the Treatment of Nonalcoholic Steatohepatitis

    TRENDS IN PHARMACOLOGICAL SCIENCES . 41(3): 199-208. Nº de citas: 52

    [doi:10.1016/j.tips.2019.12.005]

  • Palomer FX, Román-Azcona MS, Pizarro J, Planavila A, Villarroya-Gombau F, Valenzuela-Alcaraz BI, Crispi F, Sepúlveda-Martínez Á, Miguel-Escalada I, Ferrer J, Nistal JF, García R, Davidson MM, Barroso E and Vazquez M.

    SIRT3-mediated inhibition of FOS through histone H3 deacetylation prevents cardiac fibrosis and inflammation.

    signal transduction and targeted therapy . 5(1): 14-14. Nº de citas: 77

    [doi:10.1038/s41392-020-0114-1]

  • Puigoriol-Illamola D, Leiva R, Vazquez M, Vázquez S, Griñán-Ferré C and Pallàs M.

    11 beta-HSD1 Inhibition Rescues SAMP8 Cognitive Impairment Induced by Metabolic Stress

    MOLECULAR NEUROBIOLOGY . 57(1): 551-565. Nº de citas: 8

    [doi:10.1007/s12035-019-01708-4]

  • Márquez A, Aymerich J, Dei M, Rodríguez-Rodríguez R, Vazquez M, Pizarro J, Giménez-Gómez P, Merlos Á, Terés L, Serra-Graells F, Jiménez-Jorquera C, Domínguez C and Muñoz-Berbel X.

    Reconfigurable multiplexed point of Care System for monitoring type 1 diabetes patients.

    BIOSENSORS & BIOELECTRONICS . 136: 38-46. Nº de citas: 12

    [doi:10.1016/j.bios.2019.04.015]

  • Rodríguez-Calvo R, Girona J, Rodríguez M, Samino S, Barroso E, de Gonzalo-Calvo D, Guaita-Esteruelas S, Heras M, van der Meer RW, Lamb HJ, Yanes O, Correig X, Llorente-Cortés V, Vazquez M and Masana L.

    Fatty acid binding protein 4 (FABP4) as a potential biomarker reflecting myocardial lipid storage in type 2 diabetes

    METABOLISM-CLINICAL AND EXPERIMENTAL . 96: 12-21. Nº de citas: 30

    [doi:10.1016/j.metabol.2019.04.007]